The University of Chicago Header Logo

Connection

Koen Van Besien to Humans

Back to Details
This is a "connection" page, showing publications Koen Van Besien has written about Humans.
Koen Van Besien
Connection Strength
2.465
Humans
  1. High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role? Cells. 2024 10 27; 13(21).
    View in: PubMed
    Score: 0.031
  2. Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomes. Leuk Lymphoma. 2024 Oct; 65(10):1384-1397.
    View in: PubMed
    Score: 0.031
  3. Immune reconstitution inflammatory syndrome in a patient with M.haemophilum infection after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2023 12; 64(13):2214-2216.
    View in: PubMed
    Score: 0.029
  4. Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). Bone Marrow Transplant. 2023 07; 58(7):835-838.
    View in: PubMed
    Score: 0.028
  5. Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 05; 29(5):326.e1-326.e10.
    View in: PubMed
    Score: 0.028
  6. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation. Transplant Cell Ther. 2022 09; 28(9):618.e1-618.e10.
    View in: PubMed
    Score: 0.027
  7. Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match! Leuk Lymphoma. 2022 01; 63(1):7-9.
    View in: PubMed
    Score: 0.026
  8. Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. Leuk Lymphoma. 2022 02; 63(2):435-442.
    View in: PubMed
    Score: 0.025
  9. Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations. Leuk Lymphoma. 2021 10; 62(10):2306-2309.
    View in: PubMed
    Score: 0.025
  10. Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation. Leuk Lymphoma. 2021 02; 62(2):255-256.
    View in: PubMed
    Score: 0.024
  11. Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma. JAMA Oncol. 2020 12 01; 6(12):1983-1984.
    View in: PubMed
    Score: 0.024
  12. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020 10 27; 4(20):5146-5156.
    View in: PubMed
    Score: 0.024
  13. Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected? Leuk Lymphoma. 2020 12; 61(12):2783-2784.
    View in: PubMed
    Score: 0.024
  14. Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2020 12; 61(12):3024-3026.
    View in: PubMed
    Score: 0.023
  15. Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplant. 2020 12; 55(12):2298-2307.
    View in: PubMed
    Score: 0.023
  16. Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come. J Clin Oncol. 2020 05 10; 38(14):1501-1504.
    View in: PubMed
    Score: 0.023
  17. Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts? Leuk Lymphoma. 2020 04; 61(4):753-756.
    View in: PubMed
    Score: 0.023
  18. Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2020 04; 26(4):789-797.
    View in: PubMed
    Score: 0.022
  19. Donor graft genotypes versus leukemia. Leuk Lymphoma. 2019 07; 60(7):1606-1607.
    View in: PubMed
    Score: 0.022
  20. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
    View in: PubMed
    Score: 0.022
  21. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 09; 60(9):2101-2103.
    View in: PubMed
    Score: 0.022
  22. It's not all about the CNS. High dose methotrexate in DLBCL. Leuk Lymphoma. 2019 08; 60(8):1845-1847.
    View in: PubMed
    Score: 0.021
  23. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019 07; 60(7):1693-1696.
    View in: PubMed
    Score: 0.021
  24. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biol Blood Marrow Transplant. 2019 03; 25(3):466-473.
    View in: PubMed
    Score: 0.021
  25. A renaissance for autologous transplantation in follicular lymphoma? Leuk Lymphoma. 2019 01; 60(1):3-5.
    View in: PubMed
    Score: 0.020
  26. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018 12; 59(12):2829-2835.
    View in: PubMed
    Score: 0.020
  27. Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience. Transfusion. 2018 02; 58(2):339-344.
    View in: PubMed
    Score: 0.019
  28. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.
    View in: PubMed
    Score: 0.019
  29. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biol Blood Marrow Transplant. 2018 02; 24(2):288-293.
    View in: PubMed
    Score: 0.019
  30. Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. Leuk Lymphoma. 2018 02; 59(2):272-273.
    View in: PubMed
    Score: 0.019
  31. Against the odds: haplo-cord grafts protect from GvHD and relapse. Bone Marrow Transplant. 2017 12; 52(12):1590-1591.
    View in: PubMed
    Score: 0.019
  32. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation. 2017 Jan; 101(1):e34-e38.
    View in: PubMed
    Score: 0.018
  33. Second allogeneic transplantation: ever? never? or sometimes. Leuk Lymphoma. 2017 06; 58(6):1279-1280.
    View in: PubMed
    Score: 0.018
  34. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma. 2017 06; 58(6):1512-1514.
    View in: PubMed
    Score: 0.018
  35. Haploidentical cord transplantation-The best of both worlds. Semin Hematol. 2016 10; 53(4):257-266.
    View in: PubMed
    Score: 0.018
  36. HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. Leuk Lymphoma. 2016 10; 57(10):2241-2.
    View in: PubMed
    Score: 0.018
  37. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma. 2017 02; 58(2):288-297.
    View in: PubMed
    Score: 0.018
  38. Clofarabine as a bridge to hematopoietic stem cell transplant. Leuk Lymphoma. 2017 01; 58(1):230-232.
    View in: PubMed
    Score: 0.017
  39. Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. Leuk Lymphoma. 2016 11; 57(11):2555-9.
    View in: PubMed
    Score: 0.017
  40. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303.
    View in: PubMed
    Score: 0.017
  41. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.017
  42. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61.
    View in: PubMed
    Score: 0.017
  43. Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2035-2036.
    View in: PubMed
    Score: 0.017
  44. Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. Cytotherapy. 2015 Jun; 17(6):723-729.
    View in: PubMed
    Score: 0.016
  45. A new "age" for high dose therapy and autologous stem cell transplant. Leuk Lymphoma. 2015; 56(8):2233-4.
    View in: PubMed
    Score: 0.016
  46. Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? Curr Hematol Malig Rep. 2015 Mar; 10(1):1-7.
    View in: PubMed
    Score: 0.016
  47. Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015 Apr; 56(4):841-2.
    View in: PubMed
    Score: 0.016
  48. Advances in umbilical cord blood transplant: an overview of the 12th International Cord Blood Symposium, San Francisco, 5-7 June 2014. Leuk Lymphoma. 2015 Apr; 56(4):877-81.
    View in: PubMed
    Score: 0.015
  49. To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant? Leuk Lymphoma. 2014 Jun; 55(6):1221-2.
    View in: PubMed
    Score: 0.015
  50. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73.
    View in: PubMed
    Score: 0.015
  51. Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013. Leuk Lymphoma. 2014 Aug; 55(8):1735-8.
    View in: PubMed
    Score: 0.015
  52. Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leuk Lymphoma. 2014 Mar; 55(3):476-7.
    View in: PubMed
    Score: 0.015
  53. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014 May; 49(5):722-4.
    View in: PubMed
    Score: 0.015
  54. Microchimerism and allogeneic transplantation: we need the proof in the pudding. Chimerism. 2013 Jul-Sep; 4(3):109-10.
    View in: PubMed
    Score: 0.014
  55. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9.
    View in: PubMed
    Score: 0.014
  56. Peripheral-blood versus bone marrow stem cells. N Engl J Med. 2013 01 17; 368(3):287-8.
    View in: PubMed
    Score: 0.014
  57. Pre-transplant serum ferritin is prognostic but is it useful? Leuk Lymphoma. 2013 Jun; 54(6):1133-4.
    View in: PubMed
    Score: 0.014
  58. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program. 2013; 2013:56-62.
    View in: PubMed
    Score: 0.014
  59. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91.
    View in: PubMed
    Score: 0.014
  60. cGVHD of skin: simple tools, great advances. Blood. 2012 Sep 27; 120(13):2537-8.
    View in: PubMed
    Score: 0.014
  61. Therapeutic drug monitoring: a way to improve long-term immunological balance? Leuk Lymphoma. 2013 Jan; 54(1):5-6.
    View in: PubMed
    Score: 0.013
  62. Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment. Cytopathology. 2022 11; 33(6):757-759.
    View in: PubMed
    Score: 0.013
  63. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
    View in: PubMed
    Score: 0.013
  64. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol. 2011 Nov; 23(6):681-91.
    View in: PubMed
    Score: 0.013
  65. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45.
    View in: PubMed
    Score: 0.013
  66. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011 Oct; 25(5):1025-48, vi.
    View in: PubMed
    Score: 0.013
  67. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012 Mar; 53(3):371-80.
    View in: PubMed
    Score: 0.013
  68. Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma. 2012 Jan; 53(1):158-9.
    View in: PubMed
    Score: 0.013
  69. Stem cell transplantation for indolent lymphoma: a reappraisal. Blood Rev. 2011 Sep; 25(5):223-8.
    View in: PubMed
    Score: 0.013
  70. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. Leuk Lymphoma. 2011 Aug; 52(8):1415-7.
    View in: PubMed
    Score: 0.012
  71. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011 Aug; 11(8):1099-111.
    View in: PubMed
    Score: 0.012
  72. Cord blood transplant: the glass is half full--can we do better? Leuk Lymphoma. 2011 Apr; 52(4):554-5.
    View in: PubMed
    Score: 0.012
  73. Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Feb; 47(2):217-26.
    View in: PubMed
    Score: 0.012
  74. T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter? J Clin Oncol. 2011 Mar 20; 29(9):e243; author reply e244.
    View in: PubMed
    Score: 0.012
  75. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
    View in: PubMed
    Score: 0.012
  76. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
    View in: PubMed
    Score: 0.012
  77. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.
    View in: PubMed
    Score: 0.012
  78. The next frontier for stem cell transplantation: finding a donor for all. JAMA. 2010 Apr 14; 303(14):1421-2.
    View in: PubMed
    Score: 0.011
  79. Stem-cell transplantation for sickle cell disease. N Engl J Med. 2010 Mar 11; 362(10):955; author reply 956.
    View in: PubMed
    Score: 0.011
  80. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.011
  81. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J Hematol. 2009 Sep; 84(9):614-6.
    View in: PubMed
    Score: 0.011
  82. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1.
    View in: PubMed
    Score: 0.011
  83. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):610-7.
    View in: PubMed
    Score: 0.011
  84. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63.
    View in: PubMed
    Score: 0.011
  85. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treat Res. 2009; 144:209-32.
    View in: PubMed
    Score: 0.010
  86. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009; 610-8.
    View in: PubMed
    Score: 0.010
  87. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.010
  88. Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood. 2008 Sep 15; 112(6):2585-6; author reply 2586-7.
    View in: PubMed
    Score: 0.010
  89. Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects? Leuk Lymphoma. 2008 Sep; 49(9):1651-2.
    View in: PubMed
    Score: 0.010
  90. Superiority of reduced-intensity conditioning for Hodgkin's lymphoma. J Clin Oncol. 2008 Aug 20; 26(24):4045-6; author reply 4046-7.
    View in: PubMed
    Score: 0.010
  91. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41.
    View in: PubMed
    Score: 0.010
  92. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008 Jun; 14(6):719-23.
    View in: PubMed
    Score: 0.010
  93. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma. 2008; 49 Suppl 1:52-8.
    View in: PubMed
    Score: 0.010
  94. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 2008 Mar; 41(6):505-13.
    View in: PubMed
    Score: 0.010
  95. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.010
  96. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805.
    View in: PubMed
    Score: 0.010
  97. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181.
    View in: PubMed
    Score: 0.009
  98. Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leuk Lymphoma. 2007 Apr; 48(4):816-8.
    View in: PubMed
    Score: 0.009
  99. Follicular lymphoma: a historical overview. Leuk Lymphoma. 2007 Feb; 48(2):232-43.
    View in: PubMed
    Score: 0.009
  100. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.009
  101. Standardizing chronic graft-versus-host disease. Future Oncol. 2006 Aug; 2(4):459-62.
    View in: PubMed
    Score: 0.009
  102. Toxicity of high dose BCNU: how much is too much? Leuk Lymphoma. 2006 Aug; 47(8):1447-8.
    View in: PubMed
    Score: 0.009
  103. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol. 2006 May; 7(5):436-8.
    View in: PubMed
    Score: 0.009
  104. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev. 2006 Sep; 20(5):235-44.
    View in: PubMed
    Score: 0.009
  105. Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. Br J Haematol. 2006 Mar; 132(6):747-54.
    View in: PubMed
    Score: 0.009
  106. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
    View in: PubMed
    Score: 0.009
  107. Hematopoietic stem cell transplantation for myelofibrosis. Semin Oncol. 2005 Aug; 32(4):414-21.
    View in: PubMed
    Score: 0.008
  108. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.008
  109. Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant. Curr Treat Options Oncol. 2005 Jul; 6(4):279-87.
    View in: PubMed
    Score: 0.008
  110. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70.
    View in: PubMed
    Score: 0.008
  111. Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfus Apher Sci. 2005 Feb; 32(1):45-53.
    View in: PubMed
    Score: 0.008
  112. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia. 2005 Jan; 19(1):31-3.
    View in: PubMed
    Score: 0.008
  113. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant. 2004 Dec; 34(11):929-38.
    View in: PubMed
    Score: 0.008
  114. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
    View in: PubMed
    Score: 0.008
  115. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2025 Jan 10; 43(2):201-213.
    View in: PubMed
    Score: 0.008
  116. Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors). Transplant Cell Ther. 2024 Nov; 30(11):1100.e1-1100.e11.
    View in: PubMed
    Score: 0.008
  117. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 2024 06 25; 8(12):3001-3012.
    View in: PubMed
    Score: 0.008
  118. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94.
    View in: PubMed
    Score: 0.008
  119. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4.
    View in: PubMed
    Score: 0.008
  120. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nat Commun. 2024 Feb 06; 15(1):974.
    View in: PubMed
    Score: 0.007
  121. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells. Cancer Res. 2024 01 02; 84(1):101-117.
    View in: PubMed
    Score: 0.007
  122. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program. 2004; 203-20.
    View in: PubMed
    Score: 0.007
  123. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6.
    View in: PubMed
    Score: 0.007
  124. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15; 102(10):3521-9.
    View in: PubMed
    Score: 0.007
  125. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13.
    View in: PubMed
    Score: 0.007
  126. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 05 04; 141(18):2194-2205.
    View in: PubMed
    Score: 0.007
  127. Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell Death Dis. 2023 05 04; 14(5):305.
    View in: PubMed
    Score: 0.007
  128. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6.
    View in: PubMed
    Score: 0.007
  129. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023 03 16; 186(6):1115-1126.e8.
    View in: PubMed
    Score: 0.007
  130. Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia. 2003 Jan; 17(1):271-2.
    View in: PubMed
    Score: 0.007
  131. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2022 09; 57(9):1445-1447.
    View in: PubMed
    Score: 0.007
  132. Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. Blood. 2002 Jun 01; 99(11):4251-2; author reply 4252.
    View in: PubMed
    Score: 0.007
  133. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8.
    View in: PubMed
    Score: 0.007
  134. Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40.
    View in: PubMed
    Score: 0.006
  135. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma. 2022 02; 63(2):473-477.
    View in: PubMed
    Score: 0.006
  136. Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2021 10 05; 73(7):1257-1265.
    View in: PubMed
    Score: 0.006
  137. Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplant Cell Ther. 2021 12; 27(12):993.e1-993.e8.
    View in: PubMed
    Score: 0.006
  138. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia. 2001 Sep; 15(9):1317-25.
    View in: PubMed
    Score: 0.006
  139. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant. 2001 Sep; 28(6):545-9.
    View in: PubMed
    Score: 0.006
  140. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62.
    View in: PubMed
    Score: 0.006
  141. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001 Mar 15; 19(6):1855-64.
    View in: PubMed
    Score: 0.006
  142. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leuk Lymphoma. 2021 07; 62(7):1629-1638.
    View in: PubMed
    Score: 0.006
  143. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404.
    View in: PubMed
    Score: 0.006
  144. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.006
  145. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020 10 23; 71(7):1693-1700.
    View in: PubMed
    Score: 0.006
  146. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021 01; 203(1):96-104.
    View in: PubMed
    Score: 0.006
  147. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9.
    View in: PubMed
    Score: 0.006
  148. Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA Cancer J Clin. 2020 09; 70(5):349-354.
    View in: PubMed
    Score: 0.006
  149. Hematological manifestations of COVID-19. Leuk Lymphoma. 2020 12; 61(12):2790-2798.
    View in: PubMed
    Score: 0.006
  150. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020 Aug; 22(4):e13336.
    View in: PubMed
    Score: 0.006
  151. Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leuk Lymphoma. 2020 07; 61(7):1529-1534.
    View in: PubMed
    Score: 0.006
  152. An update on options of therapy for aggressive mantle cell lymphoma. Leuk Lymphoma. 2020 09; 61(9):2036-2049.
    View in: PubMed
    Score: 0.006
  153. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv. 2020 02 25; 4(4):740-754.
    View in: PubMed
    Score: 0.006
  154. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020 02 11; 4(3):560-572.
    View in: PubMed
    Score: 0.006
  155. Allogeneic transplantation for low-grade lymphoma: long-term follow-up. J Clin Oncol. 2000 Feb; 18(3):702-3.
    View in: PubMed
    Score: 0.006
  156. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep. 2019 07 23; 9(1):10634.
    View in: PubMed
    Score: 0.005
  157. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2019 12; 54(12):2027-2038.
    View in: PubMed
    Score: 0.005
  158. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631.
    View in: PubMed
    Score: 0.005
  159. The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019 08; 60(8):2091-2093.
    View in: PubMed
    Score: 0.005
  160. Colonization With Levofloxacin-resistant Extended-spectrum ß-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2018 11 13; 67(11):1720-1728.
    View in: PubMed
    Score: 0.005
  161. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019 07; 54(7):1058-1066.
    View in: PubMed
    Score: 0.005
  162. Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. Biol Blood Marrow Transplant. 2019 02; 25(2):e60-e64.
    View in: PubMed
    Score: 0.005
  163. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01; 92(5):1832-6.
    View in: PubMed
    Score: 0.005
  164. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998 Feb 15; 91(4):1178-84.
    View in: PubMed
    Score: 0.005
  165. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777.
    View in: PubMed
    Score: 0.005
  166. Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. J Clin Pathol. 2018 Jul; 71(7):626-630.
    View in: PubMed
    Score: 0.005
  167. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.
    View in: PubMed
    Score: 0.005
  168. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998 Jan; 16(1):63-9.
    View in: PubMed
    Score: 0.005
  169. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.005
  170. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S54-8.
    View in: PubMed
    Score: 0.005
  171. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. Bone Marrow Transplant. 2017 Dec; 52(12):1643-1650.
    View in: PubMed
    Score: 0.005
  172. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
    View in: PubMed
    Score: 0.005
  173. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6.
    View in: PubMed
    Score: 0.005
  174. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. Leuk Lymphoma. 2018 01; 59(1):256-258.
    View in: PubMed
    Score: 0.005
  175. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol. 1997 Jun; 8(6):515-24.
    View in: PubMed
    Score: 0.005
  176. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol. 1997 May; 65(2):366-9.
    View in: PubMed
    Score: 0.005
  177. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997 May; 19(10):977-82.
    View in: PubMed
    Score: 0.005
  178. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937.
    View in: PubMed
    Score: 0.005
  179. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42.
    View in: PubMed
    Score: 0.004
  180. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103.
    View in: PubMed
    Score: 0.004
  181. Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct; 51(10):1342-1349.
    View in: PubMed
    Score: 0.004
  182. Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. Clin Infect Dis. 2016 08 15; 63(4):565-8.
    View in: PubMed
    Score: 0.004
  183. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016 08; 22(8):1348-1356.
    View in: PubMed
    Score: 0.004
  184. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307.
    View in: PubMed
    Score: 0.004
  185. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016 May; 22(5):965-70.
    View in: PubMed
    Score: 0.004
  186. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.004
  187. Autologous bone marrow transplantation for leukemia and lymphoma. Cancer Treat Res. 1996; 84:207-59.
    View in: PubMed
    Score: 0.004
  188. Treatment of relapse after allogeneic bone marrow transplantation. Cancer Treat Res. 1996; 84:279-90.
    View in: PubMed
    Score: 0.004
  189. Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion. 2016 Apr; 56(4):893-8.
    View in: PubMed
    Score: 0.004
  190. Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. J Clin Virol. 2015 Oct; 71:51-8.
    View in: PubMed
    Score: 0.004
  191. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34.
    View in: PubMed
    Score: 0.004
  192. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102.
    View in: PubMed
    Score: 0.004
  193. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995 Apr; 15(4):549-55.
    View in: PubMed
    Score: 0.004
  194. A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion. 2015 Aug; 55(8):2010-6.
    View in: PubMed
    Score: 0.004
  195. How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. Transfusion. 2015 Jun; 55(6):1147-53.
    View in: PubMed
    Score: 0.004
  196. High-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant. 1995 Feb; 15(2):321-3.
    View in: PubMed
    Score: 0.004
  197. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar; 21(3):552-8.
    View in: PubMed
    Score: 0.004
  198. Controversies in multiple myeloma: to transplant or not? Curr Hematol Malig Rep. 2014 Dec; 9(4):360-7.
    View in: PubMed
    Score: 0.004
  199. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014 Sep; 12(9):565-73.
    View in: PubMed
    Score: 0.004
  200. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.004
  201. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014 Dec; 55(12):2858-65.
    View in: PubMed
    Score: 0.004
  202. Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8.
    View in: PubMed
    Score: 0.004
  203. Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection. Chimerism. 2014; 5(2):24-39.
    View in: PubMed
    Score: 0.004
  204. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
    View in: PubMed
    Score: 0.004
  205. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70.
    View in: PubMed
    Score: 0.004
  206. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013 Oct; 163(1):55-61.
    View in: PubMed
    Score: 0.004
  207. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013 Sep 01; 31(25):3100-9.
    View in: PubMed
    Score: 0.004
  208. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.
    View in: PubMed
    Score: 0.004
  209. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1040-5.
    View in: PubMed
    Score: 0.004
  210. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):831-7.
    View in: PubMed
    Score: 0.003
  211. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9.
    View in: PubMed
    Score: 0.003
  212. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9.
    View in: PubMed
    Score: 0.003
  213. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant. 2013 Mar; 19(3):429-34.
    View in: PubMed
    Score: 0.003
  214. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine. 2013 Jan; 61(1):329-35.
    View in: PubMed
    Score: 0.003
  215. Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leuk Lymphoma. 2013 Apr; 54(4):885-8.
    View in: PubMed
    Score: 0.003
  216. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1867-75.
    View in: PubMed
    Score: 0.003
  217. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
    View in: PubMed
    Score: 0.003
  218. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.
    View in: PubMed
    Score: 0.003
  219. Relapsing polychondritis: a paraneoplastic syndrome associated with myelodysplastic syndromes. Am J Hematol. 1992 May; 40(1):47-50.
    View in: PubMed
    Score: 0.003
  220. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8.
    View in: PubMed
    Score: 0.003
  221. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7.
    View in: PubMed
    Score: 0.003
  222. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.003
  223. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1255-64.
    View in: PubMed
    Score: 0.003
  224. Pregnancy-associated aplastic anemia--report of 3 cases. Eur J Haematol. 1991 Oct; 47(4):253-6.
    View in: PubMed
    Score: 0.003
  225. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1775-82.
    View in: PubMed
    Score: 0.003
  226. Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thromb Res. 1991 Apr; 62(1-2):23-9.
    View in: PubMed
    Score: 0.003
  227. Personalized treatment of lymphoma: promise and reality. Semin Oncol. 2011 Apr; 38(2):225-35.
    View in: PubMed
    Score: 0.003
  228. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54.
    View in: PubMed
    Score: 0.003
  229. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
    View in: PubMed
    Score: 0.003
  230. Characteristics of engraftment after repeated autologous bone marrow transplantation. Exp Hematol. 1990 Aug; 18(7):785-8.
    View in: PubMed
    Score: 0.003
  231. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
    View in: PubMed
    Score: 0.003
  232. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Jan; 17(1):124-32.
    View in: PubMed
    Score: 0.003
  233. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.003
  234. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8.
    View in: PubMed
    Score: 0.003
  235. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4.
    View in: PubMed
    Score: 0.003
  236. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010 Apr; 16(4):443-68.
    View in: PubMed
    Score: 0.003
  237. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010 Feb 20; 28(6):1038-46.
    View in: PubMed
    Score: 0.003
  238. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Jun; 45(6):1068-76.
    View in: PubMed
    Score: 0.003
  239. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64.
    View in: PubMed
    Score: 0.003
  240. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan; 16(1):35-45.
    View in: PubMed
    Score: 0.003
  241. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1394-9.
    View in: PubMed
    Score: 0.003
  242. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009 Sep; 50(9):1412-21.
    View in: PubMed
    Score: 0.003
  243. Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Aug; 15(8):903-9.
    View in: PubMed
    Score: 0.003
  244. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 May 21; 113(21):5074-82.
    View in: PubMed
    Score: 0.003
  245. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan; 15(1):109-17.
    View in: PubMed
    Score: 0.003
  246. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.003
  247. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008 Dec; 14(12):1323-33.
    View in: PubMed
    Score: 0.003
  248. Epidemiology of vancomycin-resistant enterococci among patients on an adult stem cell transplant unit: observations from an active surveillance program. Infect Control Hosp Epidemiol. 2008 Nov; 29(11):1019-25.
    View in: PubMed
    Score: 0.003
  249. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug; 14(8):904-12.
    View in: PubMed
    Score: 0.003
  250. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 01; 112(7):2667-74.
    View in: PubMed
    Score: 0.003
  251. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.002
  252. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb; 14(2):236-45.
    View in: PubMed
    Score: 0.002
  253. Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem. 2008 Mar 14; 283(11):6997-7006.
    View in: PubMed
    Score: 0.002
  254. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun; 18(6):1071-9.
    View in: PubMed
    Score: 0.002
  255. Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2007 Apr; 48(4):829-32.
    View in: PubMed
    Score: 0.002
  256. Severe intestinal graft-versus-host disease following autologous stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):391-2.
    View in: PubMed
    Score: 0.002
  257. Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncol Nurs Forum. 2006 May 03; 33(3):614-24.
    View in: PubMed
    Score: 0.002
  258. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):541-51.
    View in: PubMed
    Score: 0.002
  259. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6.
    View in: PubMed
    Score: 0.002
  260. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
    View in: PubMed
    Score: 0.002
  261. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005 Feb; 46(2):239-42.
    View in: PubMed
    Score: 0.002
  262. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004 Dec 01; 104(12):3797-803.
    View in: PubMed
    Score: 0.002
  263. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
    View in: PubMed
    Score: 0.002
  264. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003 Oct 15; 21(20):3744-53.
    View in: PubMed
    Score: 0.002
  265. Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. Transfusion. 2003 Sep; 43(9):1317-21.
    View in: PubMed
    Score: 0.002
  266. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.
    View in: PubMed
    Score: 0.002
  267. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr 01; 101(7):2476-82.
    View in: PubMed
    Score: 0.002
  268. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun. 2002 Oct 04; 297(4):760-4.
    View in: PubMed
    Score: 0.002
  269. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002 Jun 15; 168(12):5984-8.
    View in: PubMed
    Score: 0.002
  270. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15; 98(6):1695-700.
    View in: PubMed
    Score: 0.002
  271. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33.
    View in: PubMed
    Score: 0.002
  272. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44.
    View in: PubMed
    Score: 0.002
  273. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb; 27(4):387-96.
    View in: PubMed
    Score: 0.002
  274. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15; 19(2):406-13.
    View in: PubMed
    Score: 0.002
  275. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8.
    View in: PubMed
    Score: 0.001
  276. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7.
    View in: PubMed
    Score: 0.001
  277. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8.
    View in: PubMed
    Score: 0.001
  278. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.
    View in: PubMed
    Score: 0.001
  279. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.
    View in: PubMed
    Score: 0.001
  280. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant. 1999 Jul; 24(1):57-61.
    View in: PubMed
    Score: 0.001
  281. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81.
    View in: PubMed
    Score: 0.001
  282. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.001
  283. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999 Feb; 17(2):534-45.
    View in: PubMed
    Score: 0.001
  284. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant. 1999; 5(1):36-45.
    View in: PubMed
    Score: 0.001
  285. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93.
    View in: PubMed
    Score: 0.001
  286. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant. 1997 Sep; 20(6):491-5.
    View in: PubMed
    Score: 0.001
  287. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.
    View in: PubMed
    Score: 0.001
  288. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Jun; 3(2):76-82.
    View in: PubMed
    Score: 0.001
  289. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
    View in: PubMed
    Score: 0.001
  290. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma. 1997 May; 25(5-6):463-7.
    View in: PubMed
    Score: 0.001
  291. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
    View in: PubMed
    Score: 0.001
  292. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997 Mar; 11 Suppl 1:S32-4.
    View in: PubMed
    Score: 0.001
  293. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73.
    View in: PubMed
    Score: 0.001
  294. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Jan; 19(2):121-7.
    View in: PubMed
    Score: 0.001
  295. Invasive Aspergillus sinusitis during bone marrow transplantation. Scand J Infect Dis. 1997; 29(4):436-8.
    View in: PubMed
    Score: 0.001
  296. Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol. 1997; 18(6):453-6.
    View in: PubMed
    Score: 0.001
  297. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
    View in: PubMed
    Score: 0.001
  298. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90.
    View in: PubMed
    Score: 0.001
  299. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43.
    View in: PubMed
    Score: 0.001
  300. Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology. 1995 Dec; 46(6):811-5.
    View in: PubMed
    Score: 0.001
  301. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8.
    View in: PubMed
    Score: 0.001
  302. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995 Jun; 1(2):115-22.
    View in: PubMed
    Score: 0.001
  303. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65.
    View in: PubMed
    Score: 0.001
  304. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30.
    View in: PubMed
    Score: 0.001
  305. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 1994 Apr; 13(4):461-4.
    View in: PubMed
    Score: 0.001
  306. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994 Apr; 12(4):748-58.
    View in: PubMed
    Score: 0.001
  307. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993 Oct 15; 82(8):2324-8.
    View in: PubMed
    Score: 0.001
  308. Is interleukin 6 the physiological regulator of thrombopoiesis? Exp Hematol. 1992 Jan; 20(1):47-50.
    View in: PubMed
    Score: 0.001
  309. Human CD34+ HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. Blood Cells. 1991; 17(2):287-95.
    View in: PubMed
    Score: 0.001
  310. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood. 1990 Nov 15; 76(10):1997-2004.
    View in: PubMed
    Score: 0.001
  311. Preleukemic state preceding adult acute lymphoblastic leukemia. Am J Med. 1990 Nov; 89(5):657-62.
    View in: PubMed
    Score: 0.001
  312. Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow. J Clin Invest. 1990 Sep; 86(3):932-41.
    View in: PubMed
    Score: 0.001
  313. Characterization of human hematopoietic stem cells. Prog Clin Biol Res. 1990; 352:29-36.
    View in: PubMed
    Score: 0.001
  314. Acquired cyclic amegakaryocytic thrombocytopenia associated with an immunoglobulin blocking the action of granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1989 Jul 13; 321(2):97-102.
    View in: PubMed
    Score: 0.001
  315. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989 Jul; 7(7):932-9.
    View in: PubMed
    Score: 0.001
  316. Endoscopic sclerotherapy of esophageal varices. Long-term follow-up, recurrence, and survival. J Clin Gastroenterol. 1988 Aug; 10(4):368-72.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.